SCHEMBL7420342

SCHEMBL7420342

[CH2]c1ccc(CCC(=O)OC(C)(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
TDP1 Q9NUW8 1/20 0.41
HRH3 Q9Y5N1 2/20 0.39
F2RL1 P55085 1/20 0.38
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
NR1H2 P55055 2/20 0.37
NR1H3 Q13133 2/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP4Z1 Q86W10 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ALDH1A1 P00352 1/20 0.35
FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10982252 0.91 CYP4F2 (0.50) CYP4F2CYP4A11TDP1HRH3F2RL1
SCHEMBL1587126 0.84 MEN1 (0.45) CYP4F2CYP4A11TDP1KMT2ACA2
SCHEMBL13250321 0.84 CYP4F2 (0.49) CYP4F2CYP4A11TDP1HRH3F2RL1
SCHEMBL7420345 0.84 CYP4F2 (0.49) CYP4F2CYP4A11TDP1KMT2AALDH1A1
SCHEMBL10399807 0.84 CYP4F2 (0.62) CYP4F2CYP4A11TDP1HRH3F2RL1
SCHEMBL17066813 0.83 CYP4F2 (0.44) CYP4F2CYP4A11TDP1HRH3F2RL1
SCHEMBL15608606 0.83 CYP4F2 (0.44) CYP4F2CYP4A11TDP1HRH3F2RL1
SCHEMBL4409312 0.83 CYP4F2 (0.44) CYP4F2CYP4A11TDP1HRH3F2RL1
SCHEMBL9326099 0.83 CYP4F2 (0.44) CYP4F2CYP4A11TDP1HRH3NR1H2
SCHEMBL9792904 0.83 CYP4F2 (0.44) CYP4F2CYP4A11TDP1HRH3F2RL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420418-B1 INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE MERCK & CO., INC. 2002-07-16 US disclosed
WO-2001012183-A1 HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 2001-02-22 WO disclosed